| Patricia A Meier, MD | |
|
7301 College Blvd, Overland Park, KS 66210-1937 | |
| (913) 341-6275 | |
| (913) 341-6299 |
| Full Name | Patricia A Meier |
|---|---|
| Gender | Female |
| Speciality | Pathology - Hematology |
| Location | 7301 College Blvd, Overland Park, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487632824 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 04-24705 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Patricia A Meier, MD 7301 College Blvd, Overland Park, KS 66210-1937 Ph: (913) 341-6275 | Patricia A Meier, MD 7301 College Blvd, Overland Park, KS 66210-1937 Ph: (913) 341-6275 |
News Archive
The TRIL Centre with Get Ireland Active announces Falls Awareness Day, Thursday 4th October 2012. One in three people over the age of 65 will fall every year in Ireland. Two-thirds of this group will fall again within six months, leading to risk of hospitalisation and significant health decline. As well as physical injuries suffered, the psychological and social consequences of falling can have a huge impact on the faller.
Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.
Some employers using wellness and disease management programs to lower costs may soon face a new regulatory obstacle, the Wall Street Journal reports.
The National Cancer Institute awarded Chrysalis BioTherapeutics a $1.5 million contract to continue development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. The project is a collaboration between Chrysalis, Baylor College of Medicine, and the University of Texas Medical Branch (UTMB).
Group 42 (G42), a leading AI and Cloud Computing company based in the United Arab Emirates, and Oxford Nanopore Technologies, an advanced sequencing technology company based in the United Kingdom, announced today they have developed an unprecedented population-scale technology that rapidly and accurately detects SARS-CoV-2, the virus that causes COVID-19.
› Verified 4 days ago
Walter P. Richardson, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7800 W 110th St, Overland Park, KS 66210 Phone: 913-338-4070 Fax: 913-338-4245 | |
Michael Scott Handler, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 12408 Russell St, Overland Park, KS 66209 Phone: 913-498-3600 Fax: 913-498-3601 | |
Dr. Xiao Meng Xu, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7301 College Blvd, Ste. 110, Overland Park, KS 66210 Phone: 913-341-6297 Fax: 913-341-6299 | |
John D. L. Nolen, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5808 W 110th St, Overland Park, KS 66211 Phone: 913-696-8000 Fax: 816-302-9939 | |
Dr. William Earl Dorzab, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7301 College Blvd, Ste. 110, Overland Park, KS 66210 Phone: 913-341-6297 Fax: 913-341-6299 | |
James C Quigley, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 12300 Metcalf Ave, Overland Park, KS 66213 Phone: 816-241-0928 Fax: 816-936-8118 | |
Allison Lisle Cargnel, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 7301 College Blvd, Overland Park, KS 66210 Phone: 913-341-6275 |